1. Home
  2. NDLS vs IGC Comparison

NDLS vs IGC Comparison

Compare NDLS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NDLS
  • IGC
  • Stock Information
  • Founded
  • NDLS 1995
  • IGC 2005
  • Country
  • NDLS United States
  • IGC United States
  • Employees
  • NDLS N/A
  • IGC N/A
  • Industry
  • NDLS Restaurants
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • NDLS Consumer Discretionary
  • IGC Health Care
  • Exchange
  • NDLS Nasdaq
  • IGC Nasdaq
  • Market Cap
  • NDLS 34.3M
  • IGC 29.4M
  • IPO Year
  • NDLS 2013
  • IGC N/A
  • Fundamental
  • Price
  • NDLS $1.53
  • IGC $0.30
  • Analyst Decision
  • NDLS Strong Buy
  • IGC Strong Buy
  • Analyst Count
  • NDLS 2
  • IGC 2
  • Target Price
  • NDLS $3.00
  • IGC $3.75
  • AVG Volume (30 Days)
  • NDLS 371.0K
  • IGC 394.6K
  • Earning Date
  • NDLS 03-06-2025
  • IGC 02-18-2025
  • Dividend Yield
  • NDLS N/A
  • IGC N/A
  • EPS Growth
  • NDLS N/A
  • IGC N/A
  • EPS
  • NDLS N/A
  • IGC N/A
  • Revenue
  • NDLS $495,817,000.00
  • IGC $1,183,000.00
  • Revenue This Year
  • NDLS $0.24
  • IGC N/A
  • Revenue Next Year
  • NDLS $0.19
  • IGC $13.38
  • P/E Ratio
  • NDLS N/A
  • IGC N/A
  • Revenue Growth
  • NDLS N/A
  • IGC N/A
  • 52 Week Low
  • NDLS $0.55
  • IGC $0.27
  • 52 Week High
  • NDLS $2.68
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • NDLS 71.40
  • IGC 35.18
  • Support Level
  • NDLS $1.30
  • IGC $0.31
  • Resistance Level
  • NDLS $1.73
  • IGC $0.33
  • Average True Range (ATR)
  • NDLS 0.17
  • IGC 0.02
  • MACD
  • NDLS 0.04
  • IGC -0.00
  • Stochastic Oscillator
  • NDLS 80.20
  • IGC 3.89

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: